Table 2 Clinicopathological characteristics of the study participants (N = 555)
Characteristics | N(%) |
|---|---|
Age yr, median (range) | 54 (26–87) |
Estrogen Receptor | |
Negative | 202 (36.4) |
Positive | 353 (63.6) |
Progesterone Receptor | |
Negative | 297 (53.5) |
Positive | 258 (46.5) |
Ki-67 | |
≤ 20 | 103 (18.6) |
> 20 | 389 (70.1) |
unknown | 63 (11.3) |
Grading | |
G1 | 6 (1.1) |
G2 | 148 (26.7) |
G3 | 339 (61.1) |
unknown | 62 (11.2) |
Immunohistochemical Subtype | |
TP | 244 (44.0) |
ER or PgR positive | 109 (19.6) |
ER and PgR negative | 202 (36.4) |
Metastatic at Diagnosis | |
No | 398 (71.7) |
Yes | 157 (28.3) |
Neo−/adjuvant treatmenta | |
Yes | 363 (91.2) |
No | 35 (8.8) |
Neo−/adjuvant trastuzumaba | |
Yes | 212 (53.3) |
No | 186 (46.7) |
Metastatic Sites | |
Visceral | 397 (71.5) |
Bone-Only | 25 (4.5) |
Brain | 155 (27.9) |
Number of Metastatic Sites | |
1 | 397 (71.5) |
2 | 85 (15.3) |
> 2 | 73 (13.2) |
Disease Free Interval in months, median | |
No first-line Pertuzumab / T-DM1 in second-line | 40 |
No first-line Pertuzumab / T-DM1 subsequent lines | 53 |
First-line Pertuzumab / T-DM1 in second-line | 47 |
No first-line Pertuzumab / T-DM1 in subsequent lines | 28 |
T-DM1 in first-line | 17 |
T-DM1 treatment line | |
First-line | 25 (4.5) |
Second-line | 371 (66.8%) |
Third-line | 96 (17.3%) |
Subsequent lines | 63 (11.4%) |